KR102967623B1 - 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태 - Google Patents

액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태

Info

Publication number
KR102967623B1
KR102967623B1 KR1020227008160A KR20227008160A KR102967623B1 KR 102967623 B1 KR102967623 B1 KR 102967623B1 KR 1020227008160 A KR1020227008160 A KR 1020227008160A KR 20227008160 A KR20227008160 A KR 20227008160A KR 102967623 B1 KR102967623 B1 KR 102967623B1
Authority
KR
South Korea
Prior art keywords
delete delete
diffraction pattern
ray powder
powder diffraction
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227008160A
Other languages
English (en)
Korean (ko)
Other versions
KR20220052955A (ko
Inventor
클레어 메덴도르프
데브라 마자이크
고돈 윌키
조슈아 디. 와에트지그
브라이언 하인리히
라우렌 맥이칸
도미니크 시겔
해럴드 오머
스티븐 씨. 존스톤
Original Assignee
블루프린트 메디신즈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블루프린트 메디신즈 코포레이션 filed Critical 블루프린트 메디신즈 코포레이션
Publication of KR20220052955A publication Critical patent/KR20220052955A/ko
Application granted granted Critical
Publication of KR102967623B1 publication Critical patent/KR102967623B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227008160A 2019-08-13 2020-08-12 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태 Active KR102967623B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
US62/885,977 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Publications (2)

Publication Number Publication Date
KR20220052955A KR20220052955A (ko) 2022-04-28
KR102967623B1 true KR102967623B1 (ko) 2026-05-21

Family

ID=72193669

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008160A Active KR102967623B1 (ko) 2019-08-13 2020-08-12 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태

Country Status (15)

Country Link
US (1) US20220281879A1 (cg-RX-API-DMAC10.html)
EP (1) EP4013757A1 (cg-RX-API-DMAC10.html)
JP (2) JP7775186B2 (cg-RX-API-DMAC10.html)
KR (1) KR102967623B1 (cg-RX-API-DMAC10.html)
CN (2) CN114222745B (cg-RX-API-DMAC10.html)
AU (1) AU2020328534B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002597A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146701A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022001450A2 (cg-RX-API-DMAC10.html)
IL (1) IL290482A (cg-RX-API-DMAC10.html)
JO (1) JOP20220014A1 (cg-RX-API-DMAC10.html)
MX (2) MX2022001741A (cg-RX-API-DMAC10.html)
TW (1) TWI870440B (cg-RX-API-DMAC10.html)
UA (1) UA130650C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021030386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2026161341A1 (en) * 2025-01-21 2026-07-30 Blueprint Medicines Corporation Drug product formulations of fidrisertib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharm. Tech. Japan, 2002, Vol. 18(10), pp. 1629-1644.

Also Published As

Publication number Publication date
TWI870440B (zh) 2025-01-21
KR20220052955A (ko) 2022-04-28
AU2020328534A1 (en) 2022-03-17
JP2022544272A (ja) 2022-10-17
JP2025148406A (ja) 2025-10-07
JOP20220014A1 (ar) 2023-01-30
MX2022001741A (es) 2022-03-11
US20220281879A1 (en) 2022-09-08
WO2021030386A1 (en) 2021-02-18
EP4013757A1 (en) 2022-06-22
CN114222745A (zh) 2022-03-22
AU2020328534B2 (en) 2026-04-30
UA130650C2 (uk) 2026-04-08
BR112022002597A2 (pt) 2022-07-05
CN119638704A (zh) 2025-03-18
JP7775186B2 (ja) 2025-11-25
TW202120509A (zh) 2021-06-01
CO2022001450A2 (es) 2022-05-31
CN114222745B (zh) 2025-03-25
MX2024014312A (es) 2024-12-06
CA3146701A1 (en) 2021-02-18
IL290482A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
CN109970745A (zh) 取代的吡咯并三嗪类化合物及其药物组合物及其用途
ES2529105T3 (es) Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
TW201920160A (zh) 2-(5-(4-(2-嗎啉乙氧基)苯基)吡啶-2-基)-n-芐乙醯胺之固態形式
KR102847760B1 (ko) 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
US10561667B2 (en) Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
CN119212996A (zh) Pi3k抑制剂的结晶形式和盐及其制备方法和使用方法
WO2018149309A1 (zh) 4-苯基噻唑衍生物的晶型及其制备方法
HK40117473A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
HK40069001B (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
US20100179162A1 (en) Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide
HK40069001A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
BR112021001435A2 (pt) formas cristalinas de um inibidor de lta4h
US20240239796A1 (en) Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof
US20250188038A1 (en) Crystalline forms of n-{[(s)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazol-1-yl][4-(trifluoromethyl)benzene
US20250066346A1 (en) Solid forms of a benzthiazole-piperazinyl-oxazole compound and methods of use thereof
WO2025011618A9 (zh) 噻唑并吡嗪类化合物的盐或其结晶及其应用
WO2025223483A1 (zh) 并环含氮化合物、其晶型及其制备方法和用途
CN120344508A (zh) 苯并恶嗪酮类化合物的结晶及其制备
CN116514796A (zh) 3CLpro蛋白酶抑制剂的盐、晶型及其制备方法
CN121241043A (zh) 埃维酰胺的晶型
JP2023524622A (ja) 6-クロロ-7-(4-(4-クロロベンジル)ピペラジン-1-イル)-2-(1,3-ジメチル-1H-ピラゾール-4-イル)-3H-イミダゾ[4,5-b]ピリジンの塩及び多形体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)